Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 184

1.

The Mammalian circadian clock gene per2 modulates cell death in response to oxidative stress.

Magnone MC, Langmesser S, Bezdek AC, Tallone T, Rusconi S, Albrecht U.

Front Neurol. 2015 Jan 13;5:289. doi: 10.3389/fneur.2014.00289. eCollection 2014.

2.

Factors involved in treatment durability and immunological recovery in a cohort of HIV-positive patients receiving atazanavir-based regimens.

Giacomelli A, Oreni L, Franzetti M, Di Cristo V, Vergani B, Morosi M, Colella E, Galli M, Rusconi S.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19830. doi: 10.7448/IAS.17.4.19830. eCollection 2014.

3.

Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study.

Gagliardini R, Rossetti B, Bianco C, Rusconi S, Colafigli M, Prinapori R, Francisci D, Fantauzzi A, Orofino G, Vignale F, Di Giambenedetto S, De Luca A.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19818. doi: 10.7448/IAS.17.4.19818. eCollection 2014.

4.

Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial.

Fabbiani M, Di Giambenedetto S, Quiros-Roldan E, Latini A, Vullo V, Antinori A, Castagna A, Orofino G, Francisci D, Grilli E, Madeddu G, Grima P, Rusconi S, Del Pin B, Mondi A, Borghetti A, Focà E, Colafigli M, De Luca A, Cauda R.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19808. doi: 10.7448/IAS.17.4.19808. eCollection 2014.

5.

Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study.

Spagnuolo V, Galli L, Bigoloni A, Nozza S, Monforte Ad, Antinori A, Di Biagio A, Rusconi S, Guaraldi G, Di Giambenedetto S, Lazzarin A, Castagna A.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19806. doi: 10.7448/IAS.17.4.19806. eCollection 2014.

6.

Treatment outcome in HIV+ patients receiving 3- or 4-drug regimens during PHI.

Bottani GM, Oreni ML, Orofino G, Tau P, Di Nardo Stuppino S, Colella E, Carosella S, Guastavigna M, Ghisetti V, Micheli V, Galli M, Rusconi S.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19778. doi: 10.7448/IAS.17.4.19778. eCollection 2014.

7.

Full thickness abdominal wall defect in growing rats as a model for congenital diaphragmatic hernia prosthetic repair.

Gucciardo L, Ozog Y, Rusconi S, Lories R, Damink LO, Deprest J.

J Pediatr Surg. 2014 Oct;49(10):1458-65. doi: 10.1016/j.jpedsurg.2014.01.058. Epub 2014 Feb 10.

PMID:
25280646
8.

Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patients.

Bonora S, Calcagno A, Vigano O, Bigliano P, Marinaro L, Colella E, Orofino G, Trentini L, Tettoni MC, D'Avolio A, Mercadante S, Galli M, Di Perri G, Rusconi S.

Curr HIV Res. 2014;12(5):339-46.

PMID:
25106410
9.

Novel antiretroviral drugs and renal function monitoring of HIV patients.

Maggi P, Montinaro V, Mussini C, Di Biagio A, Bellagamba R, Bonfanti P, Calza L, Cherubini C, Corsi P, Gargiulo M, Montella F, Rusconi S.

AIDS Rev. 2014 Jul-Sep;16(3):144-51.

PMID:
25102336
10.

Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results.

Castagna A, Spagnuolo V, Galli L, Vinci C, Nozza S, Carini E, D'Arminio Monforte A, Montella F, Antinori A, Di Biagio A, Rusconi S, Lazzarin A; MODAt Study Group.

AIDS. 2014 Sep 24;28(15):2269-79. doi: 10.1097/QAD.0000000000000407.

PMID:
25058680
11.

The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.

Di Biagio A, Rusconi S, Marzocchetti A, Signori A, Schiavetti I, Bruzzone B, Monno L, Punzi G, Colao MG, Penco G, Zazzi M, De Luca A; ARCA Collaborative Group.

J Med Virol. 2014 Oct;86(10):1648-55. doi: 10.1002/jmv.24017. Epub 2014 Jul 11.

PMID:
25042976
12.

Clinical and epidemiological features of HIV/AIDS infection among migrants at first access to healthcare services as compared to Italian patients in Italy: a retrospective multicentre study, 2000-2010.

Sulis G, El Hamad I, Fabiani M, Rusconi S, Maggiolo F, Guaraldi G, Bozzi G, Bernardini C, Lichtner M, Stentarelli C, Carenzi L, Francisci D, Saracino A, Castelli F; HIV/Migrants Study Group.

Infection. 2014 Oct;42(5):859-67. doi: 10.1007/s15010-014-0648-7. Epub 2014 Jun 29.

PMID:
24973981
13.

The problem of renal function monitoring in patients treated with the novel antiretroviral drugs.

Maggi P, Montinaro V, Rusconi S, Di Biagio A, Bellagamba R, Bonfanti P, Calza L, Corsi P, Montella F, Mussini C.

HIV Clin Trials. 2014 May-Jun;15(3):87-91. doi: 10.1310/hct1503-87.

PMID:
24947532
14.

Rilpivirine resistance and the dangerous liaisons with substitutions at position 184 among patients infected with HIV-1: analysis from a national drug-resistance database (ARCA).

Rossotti R, Fonte L, Meini G, Maggiolo F, Zazzi M, Rusconi S; ARCA Collaborative Group.

J Med Virol. 2014 Sep;86(9):1459-66. doi: 10.1002/jmv.23978. Epub 2014 May 17.

PMID:
24838991
15.

Genotypic determination of HIV tropism in a cohort of patients perinatally infected with HIV-1 and exposed to antiretroviral therapy.

Di Biagio A, Parisini A, Bruzzone B, Prinapori R, Lauriola M, Paolucci S, Signori A, Barresi R, Icardi G, Calderisi S, Meini G, Dentone C, Cenderello G, Guerra M, Maccabruni A, Rusconi S, Viscoli C.

HIV Clin Trials. 2014 Jan-Feb;15(1):45-50. doi: 10.1310/hct1501-45.

PMID:
24518213
16.

Favorable therapeutic response with an antiretroviral salvage regimen in an HIV-1-positive subject infected with a CRF11-cpx virus.

Tau P, Mancon A, Mileto D, Di Nardo Stuppino S, Bottani G, Gismondo MR, Galli M, Micheli V, Rusconi S.

AIDS Res Hum Retroviruses. 2014 May;30(5):480-3. doi: 10.1089/AID.2013.0264. Epub 2013 Dec 31.

PMID:
24279648
17.

Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial.

Rusconi S, Vitiello P, Adorni F, Colella E, Focà E, Capetti A, Meraviglia P, Abeli C, Bonora S, D'Annunzio M, Di Biagio A, Di Pietro M, Butini L, Orofino G, Colafigli M, d'Ettorre G, Francisci D, Parruti G, Soria A, Buonomini AR, Tommasi C, Mosti S, Bai F, Di Nardo Stuppino S, Morosi M, Montano M, Tau P, Merlini E, Marchetti G.

PLoS One. 2013 Nov 14;8(11):e80157. doi: 10.1371/journal.pone.0080157. eCollection 2013.

18.

Cross-sectional study of community serostatus to highlight undiagnosed HIV infections with oral fluid HIV-1/2 rapid test in non-conventional settings.

Parisi MR, Soldini L, Vidoni G, Clemente F, Mabellini C, Belloni T, Nozza S, Brignolo L, Negri S, Rusconi S, Schlusnus K, Dorigatti F, Lazzarin A.

New Microbiol. 2013 Apr;36(2):121-32. Epub 2013 Mar 31.

19.

Prevalence of etravirine (ETR)-RAMs at NNRTI failure and predictors of resistance to ETR in a large Italian resistance database (ARCA).

Rusconi S, Adorni F, Bruzzone B, Di Biagio A, Meini G, Callegaro A, Punzi G, Boeri E, Pecorari M, Monno L, Gianotti N, Butini L, Galli L, Polilli E, Galli M; ARCA Collaborative Group.

Clin Microbiol Infect. 2013 Oct;19(10):E443-6. doi: 10.1111/1469-0691.12229. Epub 2013 Apr 26.

20.

Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database.

Rusconi S, Vitiello P, Adorni F, Bruzzone B, De Luca A, Micheli V, Meraviglia P, Maserati R, Di Pietro M, Colao G, Penco G, Di Biagio A, Punzi G, Monno L, Zazzi M; Antiretroviral Resistance Cohort Analysis Collaborative Group.

Clin Microbiol Infect. 2013 Oct;19(10):936-42. doi: 10.1111/1469-0691.12100. Epub 2013 Jan 4.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk